PRIMARY STUDY

Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress

Key Findings:  This study showed that in intestinal epithelium cells cannabidiol (CBD) reduced intestinal inflammation, and oxidation by restoring epithelial permeability, more so than THC, CBDA, and THCA. This suggests a potential therapeutic use of CBD in the treatment and management of intestinal bowel disease (IBD).

Type of Study:  Laboratory Study

Study Result:  Positive

Study Location(s):  Italy

Year of Pub:  2021


Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabidiolic Acid (CBD-a), Tetrahydrocannabinolic Acid (THC-a), Cannabinoid (unspecified)

Phytocannabinoid Source:  Cannabis Flower derived

Chemotype:  Chemotype III

Receptors Studied:  CB1

Route of Administration:  In vitro



Link to study